Literature DB >> 3139224

Severe reaction to diphosphonate: implications for treatment of Paget's disease.

A T Elliott1, T Murray, R M Mackie, J A Hunter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3139224      PMCID： PMC1834493          DOI： 10.1136/bmj.297.6648.592-a

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  3 in total

1.  Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.

Authors:  S H Ralston; A A Alzaid; M D Gardner; I T Boyle
Journal:  Br Med J (Clin Res Ed)       Date:  1986-06-14

2.  Single high dose aminohydroxypropylidene diphosphonate infusions to treat cancer-associated hypercalcaemia.

Authors:  B Cantwell; A L Harris
Journal:  Lancet       Date:  1986-01-18       Impact factor: 79.321

3.  Severe systemic reaction to diphosphonate bone imaging agents: skin testing to predict allergic response and a safe alternative agent.

Authors:  A Ramos-Gabatin; J A Orzel; T R Maloney; J E Murnane; R D Borchert
Journal:  J Nucl Med       Date:  1986-09       Impact factor: 10.057
  3 in total
  3 in total

Review 1.  Adverse effects of bisphosphonates. A comparative review.

Authors:  S Adami; N Zamberlan
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

2.  Long-lasting dermatological lesions after tiludronate therapy.

Authors:  C Roux; V Listrat; B Villette; M Lessana-Leibowitch; D Ethgen; C Pelissier; M Dougados; B Amor
Journal:  Calcif Tissue Int       Date:  1992-04       Impact factor: 4.333

3.  Erythroderma after clodronate treatment.

Authors:  I Pajus; P Lestang; F Lioté; A Dryll
Journal:  BMJ       Date:  1993-08-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.